Document is current

Article History

Received: 2 October 2025

Accepted: 27 January 2026

First Online: 13 February 2026

Change Date: 2 March 2026

Change Type: Update

Change Details: The article has been changed updated to include Electronic Supplementary Material 4.

Declarations

:

: K.K. reports support for the present manuscript from Daiichi Sankyo. Y.U. reports support for the present manuscript from Daiichi Sankyo and grants/contracts from Susmed, Aflac, Shionogi, and Meiji Seika Pharma. N.S., M.F., N.A., and A.O. declare no conflicts of interest. A.K. and T.I. are employees of Daiichi Sankyo Co., Ltd. K.M. reports consulting fees from Daiichi Sankyo and lecture payments from Eli Lilly Japan, Chugai Pharmaceutical, and Ono Pharmaceutical. T.A. reports grants to his institution from Shionogi, royalties from Igaku-Shoin Ltd., and consulting fees from Daiichi Sankyo. He also reports lecture/manuscript honoraria from AstraZeneca, Chugai, Daiichi Sankyo, Eisai, Eli Lilly, Kowa, Lundbeck, MSD, Meiji Seika Pharma, Merck, Nipro, Otsuka, Pfizer, Shionogi, Sumitomo Pharma, Takeda, Tsumura, UCB, Viatris, and Igaku-Shoin Ltd., all unrelated to the submitted work. He also reports patents (pending: 2020-135195, 2024-516288; issued: 7313617, institution-owned) and serves as representative director of NCU CRESS and advisor to Snom Inc. T.Y. reports institutional payments from Chugai, Taiho, Nippon Kayaku, Eli Lilly, Daiichi Sankyo, Pfizer, AstraZeneca, Seagen, MSD, Kyowa Kirin, Gilead Sciences, and Eisai, as well as honoraria for lectures from Chugai, Eisai, Daiichi Sankyo, Taiho, Nippon Kayaku, AstraZeneca, Kyowa Kirin, Pfizer, Eli Lilly, Novartis Pharma, and MSD.

: All participants will provide electronic informed consent.

: All participants will provide electronic informed consent.

: This study protocol (version 1.1; May 27, 2025) was approved by the Institutional Review Board of the non-profit organization MINS (IRB No: DS-HaaS-005). Informed consent will be obtained from all participants. The study has been registered in a publicly accessible database (University Hospital Medical Information Network Clinical Trials Registry [UMIN-CTR]; registration number: UMIN000056741; registered on 2025 Jan 17).